pyridine/obesity

FIELD OF THE INVENTION This invention relates to the field of pharmaceuticals, in particular to the field of obesity treatment. More specifically, it relates to certain 1,5,6,7-tetrahydropyrrolo[3,2-c]pyridine compounds which are useful in the treatment of obesity and obesity-related disorders, and

FIELD OF THE INVENTION The present invention relates to benzofuro[3,2-c]pyridine and azepine analogs as serotonin sub-type 6 (5-HT.sub.6) modulators and uses thereof. BACKGROUND OF THE INVENTION Various central nervous system (CNS) disorders such as anxiety, depression, motor disorders, etc., are

BRIEF DESCRIPTION OF THE INVENTION The invention relates to pyridineethanolamine derivatives, a process for their preparation and pharmaceutical preparations based on these compounds. The pyridine derivatives in accordance with the invention are compounds of the formula ##STR2## wherein n is 1 or

BRIEF DESCRIPTION OF THE INVENTION The invention relates to pyridineethanolamine derivatives a process for their preparation and pharmaceutical preparations based on these compounds. The Pyridine derivatives in accordance with the invention are compounds of the formula ##STR2## wherein n is 1 or

FIELD OF THE INVENTION Provided herein are certain pyridine and pyrimidine compounds that are PDE10 inhibitors, pharmaceutical compositions containing such compounds, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by

FIELD OF THE INVENTION Provided herein are certain pyridine and pyrimidine compounds that are PDE10 inhibitors, pharmaceutical compositions containing such compounds, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by

The invention relates to 6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives, to pharmaceutical compositions comprising the same, as well as to the use of these derivatives for the preparation of a medicament for the treatment of cathepsin S and/or cathepsin K related diseases such as

The invention relates to 6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives, to pharmaceutical compositions comprising the same, as well as to the use of these derivatives for the preparation of a medicament for the treatment of cathepsin S and/or cathepsin K related diseases such as

The invention relates to 1H-[1,2,3]triazolo[4,5-c]pyridine-4-carbonitrile derivatives, to pharmaceutical compositions comprising the same, as well as to the use of these derivatives for the preparation of a medicament for the treatment of cathepsin S related diseases such as atherosclerosis,

This invention relates to novel derivatives of 1,7'-[imidazo-[1,2-a]pyridine]5'-(6'H)ones, to the method for their preparation and to their use as anti-anxiety, anti-depressant and anti-migraine agents, and to their use as appetite stimulants useful for the treatment of anorexia. More specifically,

BACKGROUND OF THE INVENTION The invention had the object of finding novel compounds having valuable properties, in particular those which can be used for the preparation of medicaments. The present invention relates to compounds that are useful in the treatment and/or prevention of diseases mediated

The present invention relates to new aryl- and heteroarylethanol-pyridylalkylamines, process for the preparation thereof and the use thereof as production promoters in livestock and as agents for treating obesity in humans and animals. Aryl- and heteroarylethanolamines have already been disclosed.

BACKGROUND OF THE INVENTION The present invention is directed to G-protein coupled receptor (GPCR) agonists. In particular, the present invention is directed to agonists of GPR116 that are useful for the treatment of obesity, e.g. as regulators of satiety, and for the treatment of diabetes. Obesity

INCORPORATION BY REFERENCE The sequence listing ("Sequence Listing") submitted in ASCII text filed in connection with this application, 219KB, created May 21, 2014, and the Substitute Sequence Listing submitted in ASCII text created Nov. 9, 2015, 231KB, are incorporated herein by reference. FIELD OF

INCORPORATION BY REFERENCE The sequence listing ("Sequence Listing") submitted in ASCII text filed in connection with this application, created Nov. 9, 2015, 231 KB, is incorporated herein by reference. FIELD OF INVENTION The present invention is directed to compounds, their synthesis, and their use